HC Wainwright & Co. Maintains Buy on Revolution Medicines, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Revolution Medicines (NASDAQ:RVMD) but has lowered the price target from $32 to $28.

November 13, 2023 | 11:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revolution Medicines' Buy rating is maintained by HC Wainwright & Co., but the price target is reduced from $32 to $28.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, which could be positive for the stock. However, the reduction in the price target may reflect a tempered outlook on the stock's valuation or expected performance, which could have a neutral to slightly negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100